A single dose of ibogaine (10 mg/kg) in 14 patients with opioid use disorder caused an average QTc prolongation of 95 ms (range 29–146 ms); half of the subjects reached a QTc over 500 ms. No life-threatening cardiac events occurred, but severe temporary ataxia (inability to walk without support) was universal. Withdrawal and psychomimetic effects were mostly manageable; 11 of 14 patients did not return to morphine within 24 hours. The findings indicate that ibogaine induces clinically relevant but reversible QTc prolongation, bradycardia, and severe cerebellar toxicity.
A three-armed randomized controlled trial compared two co-created online mindfulness-based cognitive therapy (eMBCT) formats—group-blended and individual-unguided—against care as usual (CAU) for people with cancer. Group-blended eMBCT significantly reduced psychological distress at post-treatment and at 3-month follow-up compared to CAU, while individual-unguided eMBCT showed significant reductions only at follow-up. Both formats also improved secondary outcomes like rumination, mindfulness, decentering, and self-compassion at follow-up. The authors suggest these eMBCT formats may be accessible, potentially low-cost interventions to reduce distress in people with cancer.